Defining and measuring clinical effectiveness in the treatment of schizophrenia

被引:88
作者
Nasrallah, HA
Targum, SD
Tandon, R
McCombs, JS
Ross, R
机构
[1] Univ Cincinnati, Med Ctr, Dept Psychiat Neurol & Neurosci, Cincinnati, OH 45267 USA
[2] Pharmastar, Swarthmore, PA USA
[3] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA
[4] Univ So Calif, Dept Pharmaceut Econ & Policy, Los Angeles, CA USA
[5] Ross Editorial, Independence, VA USA
关键词
D O I
10.1176/appi.ps.56.3.273
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Expectations in treating schizophrenia are expanding beyond just controlling psychotic symptoms to include functional recovery. This report describes an approach to define and measure the clinical effectiveness of treatment in achieving these objectives. Methods: A comprehensive literature review established that there is limited information about the meaning of the term "clinical effectiveness." To address this gap a consensus conference of schizophrenia researchers was held to consider the components of clinical effectiveness in real-world community practice and how these components can best be measured. Results: The consensus of the researchers was that effective clinical treatment is characterized by four outcome domains: symptoms of disease, treatment burden, disease burden, and health and wellness. A clinical instrument to measure these four domains was constructed: Global Outcome Assessment of Life in Schizophrenia ( GOALS). In using GOALS, clinicians rate each of the four domains on a scale of 1, very much improved, to 7, very much worse. Field-testing of this instrument is planned. Conclusions: Effective treatment interventions that combine optimal pharmacotherapy and targeted psychosocial treatments are raising expectations about the prospects of functional recovery among patients with schizophrenia. GOALS is proposed as one tool that can provide busy clinicians with a simple, objective measure of the effectiveness and outcomes of the clinical treatment they provide to patients with schizophrenia.
引用
收藏
页码:273 / 282
页数:10
相关论文
共 98 条
[1]   PREDICTING MEDICATION COMPLIANCE IN A PSYCHOTIC POPULATION [J].
ADAMS, SG ;
HOWE, JT .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1993, 181 (09) :558-560
[2]   RELIABILITY AND VALIDITY OF A DEPRESSION RATING-SCALE FOR SCHIZOPHRENICS [J].
ADDINGTON, D ;
ADDINGTON, J ;
MATICKATYNDALE, E ;
JOYCE, J .
SCHIZOPHRENIA RESEARCH, 1992, 6 (03) :201-208
[3]   A DEPRESSION RATING-SCALE FOR SCHIZOPHRENICS [J].
ADDINGTON, D ;
ADDINGTON, J ;
SCHISSEL, B .
SCHIZOPHRENIA RESEARCH, 1990, 3 (04) :247-251
[4]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[5]  
[Anonymous], 1976, DHEW PUB
[6]  
[Anonymous], 1993, Multnomah Community Ability Scale: User's Manual Western Mental Health Research Center
[7]  
[Anonymous], 2000, DIAGN STAT MAN MENT
[8]  
[Anonymous], 2003, MED ILLNESS SCHIZOPH
[9]   A RATING-SCALE FOR DRUG-INDUCED AKATHISIA [J].
BARNES, TRE .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :672-676
[10]   A NEW PATIENT FOCUSED INDEX FOR MEASURING QUALITY-OF-LIFE IN PERSONS WITH SEVERE AND PERSISTENT MENTAL-ILLNESS [J].
BECKER, M ;
DIAMOND, R ;
SAINFORT, F .
QUALITY OF LIFE RESEARCH, 1993, 2 (04) :239-251